274 related articles for article (PubMed ID: 19684147)
1. Developing a standardized definition for disease "flare" in rheumatoid arthritis (OMERACT 9 Special Interest Group).
Bingham CO; Pohl C; Woodworth TG; Hewlett SE; May JE; Rahman MU; Witter JP; Furst DE; Strand CV; Boers M; Alten RE
J Rheumatol; 2009 Oct; 36(10):2335-41. PubMed ID: 19684147
[TBL] [Abstract][Full Text] [Related]
2. Minimal disease activity for rheumatoid arthritis: a preliminary definition.
Wells GA; Boers M; Shea B; Brooks PM; Simon LS; Strand CV; Aletaha D; Anderson JJ; Bombardier C; Dougados M; Emery P; Felson DT; Fransen J; Furst DE; Hazes JM; Johnson KR; Kirwan JR; Landewé RB; Lassere MN; Michaud K; Suarez-Almazor M; Silman AJ; Smolen JS; Van der Heijde DM; van Riel PL; Wolfe F; Tugwell PS
J Rheumatol; 2005 Oct; 32(10):2016-24. PubMed ID: 16206362
[TBL] [Abstract][Full Text] [Related]
3. Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop.
Bykerk VP; Lie E; Bartlett SJ; Alten R; Boonen A; Christensen R; Furst DE; Hewlett S; Leong AL; Lyddiatt A; March L; May JE; Montie P; Orbai AM; Pohl C; Scholte Voshaar M; Woodworth T; Bingham CO; Choy EH
J Rheumatol; 2014 Apr; 41(4):799-809. PubMed ID: 24584927
[TBL] [Abstract][Full Text] [Related]
4. Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group.
Alten R; Pohl C; Choy EH; Christensen R; Furst DE; Hewlett SE; Leong A; May JE; Sanderson TC; Strand V; Woodworth TG; Bingham CO;
J Rheumatol; 2011 Aug; 38(8):1745-50. PubMed ID: 21807796
[TBL] [Abstract][Full Text] [Related]
5. A tool to identify recent or present rheumatoid arthritis flare from both patient and physician perspectives: the 'FLARE' instrument.
Berthelot JM; De Bandt M; Morel J; Benatig F; Constantin A; Gaudin P; Le Loet X; Maillefert JF; Meyer O; Pham T; Saraux A; Solau-Gervais E; Spitz E; Wendling D; Fautrel B; Guillemin F;
Ann Rheum Dis; 2012 Jul; 71(7):1110-6. PubMed ID: 22072015
[TBL] [Abstract][Full Text] [Related]
6. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee.
Goldsmith CH; Boers M; Bombardier C; Tugwell P
J Rheumatol; 1993 Mar; 20(3):561-5. PubMed ID: 8478874
[TBL] [Abstract][Full Text] [Related]
7. More than Just Minutes of Stiffness in the Morning: Report from the OMERACT Rheumatoid Arthritis Flare Group Stiffness Breakout Sessions.
Orbai AM; Halls S; Hewlett S; Bartlett SJ; Leong AL; Bingham CO;
J Rheumatol; 2015 Nov; 42(11):2182-4. PubMed ID: 25729035
[TBL] [Abstract][Full Text] [Related]
8. Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials.
Maksymowych WP; Landewe R; Boers M; Garnero P; Geusens P; El-Gabalawy H; Heinegard D; Kraus VB; Lohmander S; Matyas J; Saxne T; van der Heijde D
J Rheumatol; 2007 Mar; 34(3):634-40. PubMed ID: 17343311
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary.
Bartlett SJ; Bykerk VP; Cooksey R; Choy EH; Alten R; Christensen R; Furst DE; Guillemin F; Halls S; Hewlett S; Leong AL; Lyddiatt A; March L; Montie P; Orbai AM; Pohl C; Voshaar MS; Woodworth TG; Bingham CO
J Rheumatol; 2015 Nov; 42(11):2185-9. PubMed ID: 25684764
[TBL] [Abstract][Full Text] [Related]
10. Responsiveness of the self-assessed rheumatoid arthritis disease activity index to a flare of disease activity.
Fransen J; Häuselmann H; Michel BA; Caravatti M; Stucki G
Arthritis Rheum; 2001 Jan; 44(1):53-60. PubMed ID: 11212176
[TBL] [Abstract][Full Text] [Related]
11. Validation of OMERACT preliminary rheumatoid arthritis flare domains in the NOR-DMARD study.
Lie E; Woodworth TG; Christensen R; Kvien TK; Bykerk V; Furst DE; Bingham CO; Choy EH;
Ann Rheum Dis; 2014 Oct; 73(10):1781-7. PubMed ID: 23852690
[TBL] [Abstract][Full Text] [Related]
12. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
Sesin CA; Bingham CO
Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
[TBL] [Abstract][Full Text] [Related]
13. MCID/Low Disease Activity State Workshop: low disease activity state in rheumatoid arthritis.
Wells G; Boers M; Shea B; Anderson J; Felson D; Johnson K; Kirwan J; Lassere M; Robinson V; Simon L; Strand V; van Riel P; Tugwell P
J Rheumatol; 2003 May; 30(5):1110-1. PubMed ID: 12734918
[TBL] [Abstract][Full Text] [Related]
14. Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus.
Bartlett SJ; Hewlett S; Bingham CO; Woodworth TG; Alten R; Pohl C; Choy EH; Sanderson T; Boonen A; Bykerk V; Leong AL; Strand V; Furst DE; Christensen R;
Ann Rheum Dis; 2012 Nov; 71(11):1855-60. PubMed ID: 22772326
[TBL] [Abstract][Full Text] [Related]
15. Preliminary definition of disease flare in juvenile rheumatoid arthritis.
Brunner HI; Lovell DJ; Finck BK; Giannini EH
J Rheumatol; 2002 May; 29(5):1058-64. PubMed ID: 12022323
[TBL] [Abstract][Full Text] [Related]
16. Generic quality-of-life assessment in rheumatoid arthritis.
Tugwell P; Idzerda L; Wells GA
Am J Manag Care; 2007 Dec; 13 Suppl 9():S224-36. PubMed ID: 18095786
[TBL] [Abstract][Full Text] [Related]
17. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.
Aletaha D; Landewe R; Karonitsch T; Bathon J; Boers M; Bombardier C; Bombardieri S; Choi H; Combe B; Dougados M; Emery P; Gomez-Reino J; Keystone E; Koch G; Kvien TK; Martin-Mola E; Matucci-Cerinic M; Michaud K; O'Dell J; Paulus H; Pincus T; Richards P; Simon L; Siegel J; Smolen JS; Sokka T; Strand V; Tugwell P; van der Heijde D; van Riel P; Vlad S; van Vollenhoven R; Ward M; Weinblatt M; Wells G; White B; Wolfe F; Zhang B; Zink A; Felson D
Ann Rheum Dis; 2008 Oct; 67(10):1360-4. PubMed ID: 18791055
[TBL] [Abstract][Full Text] [Related]
18. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
[TBL] [Abstract][Full Text] [Related]
19. Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design.
Maksymowych WP; Fitzgerald O; Wells GA; Gladman DD; Landewé R; Ostergaard M; Taylor WJ; Christensen R; Tak PP; Boers M; Syversen SW; Bathon JM; Ritchlin CJ; Mease PJ; Bykerk VP; Garnero P; Geusens P; El-Gabalawy H; Aletaha D; Inman RD; Kraus VB; Kvien TK; van der Heijde D
J Rheumatol; 2009 Aug; 36(8):1792-9. PubMed ID: 19671814
[TBL] [Abstract][Full Text] [Related]
20. OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis.
Gabriel S; Drummond M; Maetzel A; Boers M; Coyle D; Welch V; Tugwell P;
J Rheumatol; 2003 Apr; 30(4):886-90. PubMed ID: 12672223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
